Rasappa G Arumugham

US Patent:

6645503, Nov 11, 2003

Filed:

Mar 9, 1999

Appl. No.:

09/264747

Inventors:

Rasappa G. Arumugham - Pittsford NY
Michael A. Apicella - Solon IA
Bradford W. Gibson - Berkeley CA

Assignee:

Wyeth Holdings Corporation - Madison NJ

International Classification:

A61K 39385

US Classification:

42419711, 4241941, 4241931, 4241841, 4242031, 4242341, 4242501, 514 23, 514 54, 5361231

Abstract:

Antigenic conjugates are provided which comprise a carrier protein covalently bonded to the conserved portion of a lipopolysaccharide of a gram negative bacteria, wherein the conserved portion of the lipopolysaccharide comprises the inner core and lipid A portions of the lipopolysaccharide, the conjugate eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria.

US Patent:

7005129, Feb 28, 2006

Filed:

Nov 27, 1996

Appl. No.:

09/077572

Inventors:

Michael A. Apicella - Solon IA, US
Melvin G. Sunshine - Iowa City IA, US
Na-Gyong Lee - Incheon, KR
Bradford W. Gibson - Berkeley CA, US
Rasappa Arumugham - Pittsford NY, US

Assignee:

University of Iowa Research Foundation - Iowa City IA
The Regents of the University of California - Oakland CA

International Classification:

A61K 39/385
A61K 39/02
A61K 39/102
C07H 1/00
G01N 33/53

US Classification:

42419711, 4242341, 4242561, 4241931, 424831, 4241841, 435547, 5361271, 5361231

Abstract:

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

US Patent:

7510717, Mar 31, 2009

Filed:

Jan 12, 2006

Appl. No.:

11/330527

Inventors:

Michael A. Apicella - Solon IA, US
Melvin G. Sunshine - Iowa City IA, US
Na-Gyong Lee - Incheon, KR
Rasappa Arumugham - Pittsford NY, US
Bradford W. Gibson - Berkeley CA, US

Assignee:

University of Iowa Research Foundation - Iowa City IA

International Classification:

A61K 39/385
A61K 39/116
A61K 39/02
A61K 39/102
A61K 39/00
A01N 43/04
C07H 1/00

US Classification:

42419711, 4242561, 4242341, 4242031, 4241841, 514 23, 5361231

Abstract:

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

US Patent:

8227403, Jul 24, 2012

Filed:

Dec 17, 2004

Appl. No.:

10/583503

Inventors:

Rasappa G. Arumugham - Chapel Hill NC, US
A. Krishna Prasad - Chapel Hill NC, US
Michael Hagen - Pittsford NY, US

Assignee:

Wyeth LLC - Madison NJ
Janssen Alzheimer Immunotherapy - Dublin

International Classification:

A61K 38/00
C07K 17/00

US Classification:

514 11, 514 212, 525 5411

Abstract:

The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.

US Patent:

20040052804, Mar 18, 2004

Filed:

Aug 19, 2003

Appl. No.:

10/643314

Inventors:

Rasappa Arumugham - Chapel Hill NC, US
Michael Apicella - Solon IA, US
Bradford Gibson - Berkeley CA, US

Assignee:

Wyeth Holdings Corporation - Madison NJ

International Classification:

A61K039/00
A61K039/38

US Classification:

424/184100

Abstract:

Antigenic conjugates are provided which comprise a carrier protein covalently bonded to the conserved portion of a lipopolysaccharide of a gram negative bacteria, wherein said conserved portion of the lipopolysaccharide comprises the inner core and lipid A portions of said lipopolysaccharide, said conjugate eliciting a cross reactive immune response against heterologous strains of said gram negative bacteria.

US Patent:

20070134762, Jun 14, 2007

Filed:

Dec 17, 2004

Appl. No.:

10/583464

Inventors:

Rasappa Arumugham - Chapel Hill NC, US
A. Prasad - Chapel Hill NC, US

International Classification:

C12Q 1/68
C12P 21/06

US Classification:

435069100, 435006000

Abstract:

The present invention is directed to methods of producing conjugates of peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.

US Patent:

20080145373, Jun 19, 2008

Filed:

Aug 20, 2007

Appl. No.:

11/841919

Inventors:

Rasappa G. Arumugham - Chapel Hill NC, US
A. Krishna Prasad - Chapel Hill NC, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA
Wyeth - Madison NJ

International Classification:

A61K 39/385
A61P 43/00

US Classification:

4241791

Abstract:

The present invention is directed to methods of producing conjugates of Aβ peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.

US Patent:

20080227207, Sep 18, 2008

Filed:

Mar 13, 2008

Appl. No.:

12/048010

Inventors:

Vincent E. Turula - Holly Springs NC, US
Shaune Walters - Raleigh NC, US
Suddham Singh - Chapel Hill NC, US
Rasappa Arumugham - Chapel Hill NC, US

Assignee:

Wyeth - Madison NJ

International Classification:

G01N 33/50

US Classification:

436 43

Abstract:

A method of automated determination of saccharide concentration is provided herein. The method includes preparing one or more saccharide standards and one or more diluted polysaccharide test samples, transferring a portion of the one or more saccharide standards and the one or more diluted polysaccharide test samples along with a diluent to a series of wells in a multiwell plate, transferring a portion of an acid reagent to the series of wells in the multiwell plate, mixing the contents of the series of wells in the multiwell plate, heating and cooling the contents of the series of wells in the multiwell plate, shaking the multiwell plate, and measuring the radiant energy absorbance of the contents of the series of wells in the multiwell plate, where all steps are performed in the absence of human intervention.